Organization
The First Affiliated Hospital of Soochow University
53 clinical trials
6 abstracts
Abstract
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).Org: Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL, CSIC), Medical University of Lodz, Samodzielny Publiczny Szpital Kliniczny,
Clinical trial
An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple MyelomaStatus: Withdrawn, Estimated PCD: 2023-10-18
Clinical trial
Vedolizumab, Anti-CD25 Antibody Combined With Rapid Reduction of Glucocorticoids as Treatment of Grade 3-4 Steroid-resistant Acute Graft-versus-host Disease With Lower Gastrointestinal InvolvementStatus: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Venetoclax, Cladribine Plus Low-dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, Randomized, Controlled StudyStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Clinical Trial for the Safety and Efficacy of Induction Chemotherapy With Azacitidine+Venetoclax (VA) and Bridging CD19CD22 CAR-T Therapy in Adult Patients With Newly Diagnosed High-Risk and Ph-negative (Ph-) B-ALLStatus: Recruiting, Estimated PCD: 2024-09-10
Clinical trial
Safety and Efficacy of CD22/CD19 CAR T-cells and Autologous HSCT Sandwich Strategy as Consolidation Therapy for B-cell Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Haploidentical Hematopoietic Cell Transplantation Combined With an Unrelated Cord Blood Unit for Acute T Cell Lymphoblastic Leukemia Compared to Haploidentical Hematopoietic Cell Transplantation: a Multicenter, Randomized, Open-label TrialStatus: Recruiting, Estimated PCD: 2028-03-31
Abstract
Efficacy and safety of chidamide in combination with serplulimab and standard third-line treatments in advanced colorectal cancer: A single arm, exploratory phase 2 trial.Org: The First Affiliated Hospital of Suzhou University, Suzhou, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of Soochow University,
Clinical trial
A Multicenter, Randomized, Controlled Clinical Trial of Venetoclax, Azacytidine Combined With Chidamide for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Patients That Are Ineligible for Intensive ChemotherapyStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Multicenter, Prospective, Phase II Study of Decitabine, Venetoclax and Blinatumomab for Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Ph-Negative B-Cell Acute Lymphoblastic LeukemiaStatus: Not yet recruiting, Estimated PCD: 2026-04-25
Clinical trial
A Multi-center, Randomized Clinical Trial of Chidamide Combined With Azacytidine and the HAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia PatientsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Evaluation of Safety and Efficacy of CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Concomitant With Infusion of CD19+T Cells as Feeding CellsStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients: A Single Arm, Multi Center Clinical TrialStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Efficacy and Safety of PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allogeneic Hematopoietic Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Department of Hematology of First Affiliated Hospital of Soochow UniversityStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
IAC Regimen Versus IA Regimen as Induction Treatment for Initially Diagnosed AML Patients: a Randomized Controlled Phase III Clinical TrialStatus: Completed, Estimated PCD: 2020-01-01
Clinical trial
Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia(CML-CP) : A Multicenter, Open-lable, Real World StudyStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Single-arm Prospective Study of the Treatment in High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionStatus: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Clinical Study of Chidamide in Combination With Venetoclax and Azacitidine (VAC) for Patients With Acute Myeloid Leukemia Who Did Not Achieve CR/CRi/MLFS (PR or NR) With One Cycle of Venetoclax and Azacitidine (VA).Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Study of the Efficacy and Safety of Venetoclax Plus Azacytidine Versus Daunorubicin Plus Cytarabine in Adult Acute Myeloid Leukemia (AML) Patients With Adverse Risk FeaturesStatus: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Letermovir for the Prevention of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients Based on the Outcome of Metagenomic Next-Generation Sequencing: a Phase 2, Open Label, Single-Arm Clinical Trial.Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Study of A Venetoclax-based, Anthracycline-free Regimen in Patients With Newly Diagnosed CBFβ::MYH11-positive Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
Venetoclax, Cladribine Plus Low-dose Cytarabine for Relapsed/Refractory Philadelphia Chromosome-negative (Ph-) B-cell Acute Lymphoblastic Leukemia (B-ALL): a Single-arm, Multicenter StudyStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Selinexor in Combination With Chidamide in Unfit Relapsed/Refractory Acute Leukemia: a Phase 2, Single-Arm, Open-Label, Multi-Center Prospective Study.Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Clinical Study of Repeated Transcranial Magnetic Stimulation(rTMS) for Chronic Visceral Pain in Patients With Irritable Bowel Syndrome(IBS)Status: Recruiting, Estimated PCD: 2026-01-30
Clinical trial
Clinical Study on the Impact of Covid-19 Vaccine on Safety and Efficacy of Hematological Patients Received Allogeneic Hematopoietic Sem Cell TransplantationStatus: Withdrawn, Estimated PCD: 2023-11-01
Clinical trial
A Clinical Study on the Optimal Dose of Indomethacin Suppository for Preventing Post-ERCP PancreatitisStatus: Completed, Estimated PCD: 2023-12-06
Clinical trial
Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allogenic Hematopoietic Stem Cell TransplantationStatus: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase Ⅱ, Open Label, Single Arm, Single-Center Study to Evaluate the Efficacy and Safety of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsStatus: Completed, Estimated PCD: 2024-04-13
Clinical trial
Study of Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following High-dose Melphalan Conditioning in Patients With Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
The Efficiency and Safety of N-acetylcysteine for Prevention of Thrombotic Events After Allogenic Hematopoietic Stem Cell TransplantationStatus: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
An Open Label, Single Arm, Single-Center Exploratory Study to Evaluate the Efficacy and Safety of Selinexor and HAAG +/- HMA in Relapsed/Refractory Acute Leukemia (AML) PatientsStatus: Not yet recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 2 Study of Chidamide, Azacitidine Combined With GM Regimen for Patients With Relapsed and Refractory DLBCLStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Venetoclax (VEN)+Azacytidine (AZA) Followed by Modified BUCY Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)Status: Recruiting, Estimated PCD: 2025-01-20
Clinical trial
Low Dose Decitabine for Poor Graft Function Post Allogenic Hematopoietic Stem Cell TransplantationStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
Venetoclax + Azacytidine Followed by Modified BUCY Conditioning Regimen for High-risk Myelodysplastic Syndromes (MDS) and High-risk or Relapsed/Refractory Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)Status: Recruiting, Estimated PCD: 2025-01-20
Clinical trial
Letermovir Prophylaxis for Cytomegalovirus Infection in Haploidentical Allogeneic Hematopoietic Cell Transplant Recipients: Single-center Real-world Data in ChinaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Sitagliptin Efficacy and Safety for Prevention of Acute Graft Versus Host Disease in Patients Receiving Alternative Donor Allogeneic Hematopoietic Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
Prospective, Single-center, Single-arm, Open-label Study of Obinutuzumab, Zanubrutinib and Lenalidomide Sequential CD19/CD22 CAR-T in Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaStatus: , Estimated PCD: 2024-06-30
Clinical trial
Prospective Exploratory Clinical Study of Orelabrutinib, Pomalidomide, Rituximab Combined With miniCHOP-like Regimen in Treatment-naive Elderly Patients With DLBCLStatus: Recruiting, Estimated PCD: 2025-07-03
Clinical trial
Venetoclax Based Regimen for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Venetoclax in Combination With Homoharringtonine and Cytarabine in Newly Diagnosed Subjects With Acute Myeloid Leukemia: a Phase 2/3, the Single-arm, Open-label, Monocentric StudyStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Avapritinib in Relapsed Refractory or MRD-positive CBF-AML With KIT MutationsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multicenter, Prospective Clinical Study of Olverembatinib Combined With Blinatumomab in the Treatment of Adult de Novo Philadelphia Chromosome Positive Acute Lymphoid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
Exploratory Study to Assess the Safety and Efficacy of CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaStatus: Recruiting, Estimated PCD: 2026-04-29
Clinical trial
Open Label, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of CT0591CP Cell in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-01-29
Clinical trial
Clinical Study of the Efficacy and Safety of Chimeric Antigen Receptor T-cell Therapy Following Autologous Stem Cell Transplantation for Relapsed/Refractory B-cell Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
Clinical Study of rATG Individualized Administration for Prevention of GVHD and Maintenance of GVL in Haploidentical Hematopoietic Stem Cell Transplantation.Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Clinical Study on the Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell LymphomaStatus: Recruiting, Estimated PCD: 2023-12-14
Clinical trial
Clinical Study of the Efficacy and Safety of XPO-1 Inhibitors in Combination With CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's LymphomaStatus: , Estimated PCD: 2024-02-10
Clinical trial
An Open, Single-arm Clinical Study Evaluating the Safety and Efficacy of IBI346 Infusion in Relapsed/Refractory Multiple MyelomStatus: Completed, Estimated PCD: 2022-12-21
Clinical trial
A Prospective, Multi-Center Study to Evaluate the Efficacy and Safety of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia PatientsStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Single-center, Single-arm, Prospective Clinical Study on the Efficacy and Safety of Venetoclax and Azacitidine Combined With HAAG in the Induction Treatment of Intermediate and High-risk Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-05-30
Abstract
Harnessing the power of tumor-infiltrating lymphocytes: A first-in-human study of GT201 as monotherapy in advanced solid tumors.Org: Grit Biotechnology, The Affiliated Hospital of XuZhou Medical University, Xuzhou, China, The First Affiliated Hospital of Soochow University, Grit Biotechnology Co. Ltd, University of Southern California Marshall School of Business,
Abstract
Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010).Org: Jiangsu Province Hospital, Huai'an First People's Hospital, Nanjing Drum Tower Hospital, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Zhongda Hospital Southeast University,
Abstract
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.Org: Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Maternal and Child Health Hospital of Jiangxi Province, Shandong Cancer Hospital & Institute, The Affiliated Tumor Hospital of Zhengzhou University, The First Affiliated Hospital of Soochow University,
Abstract
OS analysis of patients with different short-term response and progression patterns of donafenib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: An exploratory subgroup analysis of ZGDH3.Org: Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China, West China Hospital, Sichuan University,
Clinical trial
Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients in Treatment of Newly Diagnosed Untreated Non-GCB DLBCL With Extranodal Involvement.Status: , Estimated PCD: 2026-05-01
Clinical trial
A Single-arm, Multi-center, Prospective Clinical Study of Mitoxantrone Hydrochloride Liposome Injection-based CMOP±R Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-08-31